atrial fibrillation, paroxysmal, recurrent
DISEASE INTERVENTION COMPARISON RESULTS
Int Heart J. 2008 May;49(3):281-93 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, paroxysmal, recurrent The Use of
beta-blockers, bisoprolol
As Treatment, Chronic
Is good Than
no comparison done
To improve symptoms and may be suppress recurrences (84% patients with diurnal AF had no recurrences?)
JAMA. 2008 Oct 15;300(15):1784-92 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, recurrent The Use of
continuous amiodarone, after electrical cardioversion
As Treatment, Chronic
Is better Than
amiodarone, episodic treatment, 1 month peri-electrical cardioversion
To reduce major events (either drug- or heart-related): 35% episodic VS 33% continouous amiodarone. All-cause mortality and cardiovascular hospitalizations were higher among those receiving episodic treatment (53% VS 34% continuous)
N Engl J Med. 2004 Dec 2;351(23):2384-91 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, paroxysmal, recurrent, mild or no cardiopathy The Use of
pill-in-the-pocket approach: self-administered oral loading of flecainide or propafenone
As Treatment, Chronic
Is useful Than
historical comparison
To reduce presumed AF recurrences, at 1.5 years (treatment successful in 84% of palpitations episodes), reducing emergency deparment visits, with 7% adverse events (1.5% severe)
Munchener Medizinische Wochenschrift. 1996;138 (12):39-46 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
G Ital Cardiol. 1996 Apr;26(4):379-90 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Curr Ther Res Clin Exp. 1995;56(11):1154-1168 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Cardiology Review 2002;19(9):18-21 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 2001 Sep 15;88(6):640-5 Randomized Controlled Trial
IN StudyID: Bellandi 2001, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 1989 Apr 1;63(12):817-9 Cross-Over
IN StudyID: Connolly 1989, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone
As Treatment, Chronic
Is equal Than
placebo
To AF symptomatic recurrence
Am Heart J. 1992 Sep;124(3):645-50 Cross-Over
IN StudyID: Lau 1992, atrial fibrillation, paroxysmal, recurrent The Use of
flecainide
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 2 months
New Trends in Arrhytmias. 1991;7(4):693-698 Cross-Over
IN StudyID: Massacci 1991, atrial fibrillation, paroxysmal, recurrent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects - at 4 weeks
J Cardiovasc Pharmacol. 1989 Jan;13(1):32-6 Cross-Over
IN StudyID: Van Wijk 1989, atrial fibrillation, paroxysmal, recurrent The Use of
flecainide
As Treatment, Chronic
Is better Than
quinidine
To AF recurrence, adverse effects - at 3 months